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Evidence indicates that neuroinflammation contributes to motor neuron degeneration in
amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease leading to
progressive muscular paralysis. However, it remains elusive whether inflammatory cells can
interact with degenerating distal motor axons, influencing the progressive denervation of
neuromuscular junctions (NMJs). By analyzing the muscle extensor digitorum longus (EDL)
following paralysis onset in the SOD1G93A rat model, we have observed a massive
infiltration and degranulation of mast cells, starting after paralysis onset and correlating with
progressive NMJ denervation. Remarkably, mast cells accumulated around degenerating
motor axons and NMJs, and were also associated with macrophages. Mast cell
accumulation and degranulation in paralytic EDL muscle was prevented by systemic
treatment over 15 days with masitinib, a tyrosine kinase inhibitor currently in clinical trials for
ALS exhibiting pharmacological activity affecting mast cells and microglia. Masitinib-
induced mast cell reduction resulted in a 35% decrease in NMJ denervation and reduced
motor deficits as compared with vehicle-treated rats. Masitinib also normalized macrophage
infiltration, as well as regressive changes in Schwann cells and capillary networks
observed in advanced paralysis. These findings provide evidence for mast cell contribution
to distal axonopathy and paralysis progression in ALS, a mechanism that can be
therapeutically targeted by masitinib.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness and 
paralysis, caused by motor neuron degeneration and distal motor axonopathy (1, 2). In general, ALS is a rapidly 
progressing disease with survival of 3–5 years after the time of diagnose. The cause of ALS remains largely 
unknown, and there exists an urgent unmet medical need for drugs that can stop or delay disease progression. In 
the CNS, ALS is typically accompanied by neuroinflammation involving the emergence of reactive microglia, 
astrocytes, and aberrant glial phenotypes (3–5). Evidence also shows activation of circulating immune cells (6), 
as well as immune cell infiltration of the ALS-degenerating peripheral nerves containing motor axons (7–10).
Complex, yet not completely understood, mechanisms underlie the progressive retraction of  axons 
from the muscular motor endplates, a key pathological event leading to paralysis in ALS. Most neuromus-
cular pathological features of  familial and sporadic ALS are reproduced in transgenic mice and rats overex-
pressing the human ALS-linked mutation of  the superoxide dismutase-1 (SOD1G93A) (11–13). It is reported 
that motor neuron degeneration in mutant SOD1 mice starts peripherally by a distal axonopathy of  the 
motor nerve branches innervating the neuromuscular junctions (NMJs) before overt loss of  motor neuron 
cell bodies (2, 14). Altered axonal transport, defective mitochondria function in motor axon terminals, dys-
Evidence indicates that neuroinflammation contributes to motor neuron degeneration in 
amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease leading to progressive 
muscular paralysis. However, it remains elusive whether inflammatory cells can interact with 
degenerating distal motor axons, influencing the progressive denervation of neuromuscular 
junctions (NMJs). By analyzing the muscle extensor digitorum longus (EDL) following paralysis 
onset in the SOD1G93A rat model, we have observed a massive infiltration and degranulation of mast 
cells, starting after paralysis onset and correlating with progressive NMJ denervation. Remarkably, 
mast cells accumulated around degenerating motor axons and NMJs, and were also associated with 
macrophages. Mast cell accumulation and degranulation in paralytic EDL muscle was prevented by 
systemic treatment over 15 days with masitinib, a tyrosine kinase inhibitor currently in clinical trials 
for ALS exhibiting pharmacological activity affecting mast cells and microglia. Masitinib-induced 
mast cell reduction resulted in a 35% decrease in NMJ denervation and reduced motor deficits as 
compared with vehicle-treated rats. Masitinib also normalized macrophage infiltration, as well as 
regressive changes in Schwann cells and capillary networks observed in advanced paralysis. These 
findings provide evidence for mast cell contribution to distal axonopathy and paralysis progression 
in ALS, a mechanism that can be therapeutically targeted by masitinib.
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functional Schwann cells, and defective stabilization of  NMJs have been proposed as potential pathogenic 
defects triggering the “dying back” of  motor axons (15–17). Finally, evidence for such dying back motor 
neuropathy has also been found in some clinical forms of  ALS (2, 16), suggesting a key pathogenic event 
that could be targeted by therapeutic interventions.
The role of  immune cells influencing NMJ alterations in ALS remains unknown. Previous reports 
have found macrophage infiltration of  peripheral nerves and skeletal muscle in ALS patients and trans-
genic mice (7, 18). However, it remains unknown whether other immune cells interact with motor nerve 
endings and NMJs. Mast cells are hematopoietic-derived immune cells, whose precursors migrate within 
tissues reaching maturation and differentiation (19). Mast cells are constitutive immune cells in skeletal 
muscle, being enriched in tendon regions and perimysium — but in low numbers in the endomysium 
(20). Mast cells likely play a physiological role in muscle repair and remodeling through the release of  
different trophic and inflammatory factors, as well as vasoactive mediators (21). Mast cells accumulate 
in the muscle endomysium following injury or primary myopathies (21, 22), with a potential of  causing 
direct lysis of  myofibers through the release of  proteases (23). In ALS patients, an increased number of  
mast cells have been described in CNS regions of  active degeneration (e.g., motor and prefrontal cortex 
and pyramidal tracts; ref. 24), suggesting their contribution to neuroinflammation. Nonetheless, scarce 
information exists about the behavior of  mast cells in ALS-affected muscles, such as whether they have a 
potential role modulating NMJ innervation or triggering local chronic inflammation.
Masitinib mesylate is a selective tyrosine kinase inhibitor that mainly targets type III growth factor recep-
tors including c-Kit, CSF-1 receptor (CSF-1R), and platelet-derived growth factor receptors (PDGF-R), as 
well as Lyn and Fyn kinases (25–27). These receptors synergistically signal proliferation and migration of  
cancer and hematopoietic cells, including macrophages. By targeting c-Kit, Lyn, and Fyn, masitinib is partic-
ularly efficient in controlling the survival, differentiation, and degranulation of  mast cells and, thus, modulat-
ing the mast cell–induced array of  proinflammatory and vasoactive effects (25, 28). Accordingly, clinical trials 
have shown therapeutic effects of  masitinib in cases of  mastocytosis, a rare disease characterized by abnormal 
accumulation and activation of  mast cells in various tissues and organs (28). Masitinib was also shown to 
beneficially modulate CNS function in multiple sclerosis (29), stroke (30), and Alzheimer’ s disease (31). In 
addition, a recent phase III clinical trial with masitinib in ALS has shown promising therapeutic effects in a 
significant group of  patients, slowing the deterioration of  motor functions and reducing the decline in quality 
of  life (32). However, the mechanisms of  action of  masitinib remain largely unexplored, considering that the 
drug acts on multiple organs and cell types expressing type III tyrosine kinase receptors.
The clinical trial of  masitinib in ALS was based on a previous study performed in transgenic rats 
bearing the ALS-linked SOD1G93A mutation, which showed that postparalysis survival of  rats can be 
significantly extended by systemic treatment with masitinib starting up to 7 days after disease onset 
(27). This result is significant, considering that in this animal model, a fulminant paralysis develops 
in rats aged 5–6 months, rapidly progressing from abnormal gait to complete loss of  motor function 
in a period of  2–3 weeks (27). The therapeutic effect of  masitinib in ALS rats was associated with the 
inhibition of  CSF-1R in microglia and aberrant glial cells that surround degenerating spinal motor 
neurons (33, 34). Because masitinib is a multifaceted drug affecting multiple immune cell types, we 
hypothesized that the protective effect of  masitinib in ALS likely involves other inflammatory cell 
types such as mast cells and macrophages in addition to glial cells.
Our primary objective was to search for a morphological interaction between degenerating motor 
nerve endings and mast cells during the development of  paralysis in the hind limb muscle extensor 
digitorum longus (EDL), a fast-fatigable muscle that becomes largely denervated in the SOD1G93A rat 
model (35). We also explored whether the pharmacologic reduction of  mast cells, by means of  sys-
temic treatment with masitinib, could modulate the rate of  NMJ denervation. Here, we report a sharp 
increase in mast cell number and degranulation infiltrating the EDL muscle — starting after paralysis 
onset — and the protective effect of  masitinib preventing progressive NMJ denervation.
Results
Endomysial infiltration and degranulation of  mast cells correlate with paralysis progression. In healthy skeletal muscle, 
mast cells are mainly located at the perimysium and epimysium, with only a small fraction in the endomysi-
um (20). In contrast, endomysial mast cells have been reported to accumulate in response to muscle denerva-
tion or myopathies (22, 36), suggesting that mast cells are part of  a broader inflammatory reaction. Because 
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there are no previous studies on the behavior of  mast cells in ALS-affected muscles, we analyzed the mast cell 
number and their phenotypic features in longitudinal sections of  the SOD1G93A rat fast-fatigable EDL muscle. 
The temporal sequence of  events was analyzed at the paralysis onset and after 15 days during advanced paral-
ysis stages, and it was compared with nontransgenic (NonTg) age-matched rats. In the NonTg rat muscles, a 
low density of  mast cells resided in the endomysium, typically displaying uniform granularity when stained 
with toluidine blue. Compared with NonTg EDL muscle, the density of  endomysial mast cells increased by 
2-fold at paralysis onset (7 vs. 14 cells/mm2) and then sharply augmented by 5-fold in the following 2 weeks of  
paralysis progression (7 vs. 39 cells/mm2) (Figure 1, A–C). During advanced paralysis, endomysial mast cells 
were grouped and arranged either in line along some interstitial spaces (Figure 1A) or close to neuromuscular 
elements (see below), typically displaying increased size and with frequent occurrences of  explosive degranu-
lation (Figure 1B). The density of  degranulating mast cells, a more relevant measure of  mast cell activity and 
influence in the neuromuscular microenvironment, increased by 8-fold in advanced paralysis EDL muscle 
as compared with NonTg controls (Figure 1C). Additionally, mast cells in EDL muscle displayed strong 
immunostaining for tryptase, chymase, and the tyrosine kinase receptor c-Kit, with their colocalization being 
considered as a specific mast cell marker (Figure 1D).
Mast cells cluster together with motor nerve endings, NMJs, and macrophages during paralysis progression. Peripher-
al sensory and autonomic nerves have been shown to functionally interact with mast cells, being a mechanism 
underlying neurogenic inflammation (37, 38). However, whether motor nerve terminals interact with mast 
cells during ALS paralysis progression is presently unknown. Therefore, we used mechanically dissociated 
EDL muscle preparations to analyze whether the sharp increase of  mast cells after paralysis onset was spa-
tially associated with the degenerating motor fibers and NMJs. Figure 2A shows comparative fields of  motor 
nerve branches interacting with motor endplates at different stages of  paralysis. In NonTg and SOD1G93A 
onset EDL muscles, only a few mast cells were found in close proximity of  motor nerve endings and NMJs 
(Figure 2A). By contrast, in the advanced paralysis stage, tryptase- and chymase-expressing mast cells were 
found clustering near or in close contact with degenerating motor nerve endings and NMJs (Figure 2, A 
and B). Quantitative analysis performed in the whole-mounted EDL muscle showed a significant increase in 
mast cell density in those areas surrounding the denervated motor nerve terminals and NMJs (neuromuscu-
lar compartment), as compared with muscle parenchyma lacking NMJs (Figure 2B). In advanced paralysis, 
mast cells also consistently interacted with macrophages expressing CD11b/Iba1 and CD68 (Figure 2C and 
Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.95934DS1). Endomysial CD11b+ macrophages also progressively accumulated within degenerating 
EDL muscle after paralysis onset and localized in close contact with NMJs. In parallel, CSF-1R immunoreac-
tivity augmented near neuromuscular compartments (Supplemental Figure 1).
Postparalysis tyrosine kinase inhibition with masitinib prevents mast cell accumulation into EDL muscle during 
advanced paralysis. Masitinib has proven to exert therapeutic effects in ALS patients (32) and to prolong 
postparalysis survival in SOD1G93A rats (27). Because masitinib potently inhibits the stem cell factor/c-
Kit pathway in mast cells, we reasoned that systemic administration of  masitinib (30 mg/kg/d) during 
15 days after paralysis onset could prevent the augmentation of  muscular mast cells in symptomatic rats. 
Moreover, because masitinib is not expected to exert direct neuroprotection on motor nerve terminals, the 
masitinib-induced mast cell downregulation would serve as evidence for their pathogenic contribution to 
NMJ denervation. Figure 3A shows representative transversal sections of  the EDL muscle in advanced 
paralysis from SOD1G93A rats treated with vehicle and with masitinib. Compared with vehicle-treated rats, 
masitinib almost completely prevented mast cell accumulation and degranulation, the cell numbers being 
nonsignificantly different than those of  rats at the onset of  paralysis (Figure 3, A and B). Masitinib treat-
ment also prevented the interstitial infiltration of  macrophages assessed by CD11b staining in the EDL 
muscle during advanced paralysis (Figure 3C). These results are consistent with a synergistic action of  
masitinib-downregulating inflammatory activity of  mast cells and inhibiting CSF-1R in macrophages (27).
Masitinib-induced reduction of  mast cells was associated with preserved innervation of  motor endplates. Paralysis pro-
gression in ALS correlates with anatomical contact between muscular nerve terminals and motor endplates (39, 
40). Thus, we have analyzed the effect of masitinib-induced downregulation of mast cells on the NMJ inner-
vation pattern in the EDL muscle. Figure 4 shows representative microscopic fields illustrating the sequence of  
progressive denervation between paralysis onset and advanced paralysis as compared with NonTg EDL mus-
cles. About 35% of EDL muscle motor endplates at onset exhibited denervation, as assessed by NMJ occupancy 
calculated as motor endplates devoid of presynaptic terminals (yellow colocalization in Figure 4A). Fifteen days 
4insight.jci.org   https://doi.org/10.1172/jci.insight.95934
R E S E A R C H  A R T I C L E
after paralysis progression, the motor phenotype advanced into advanced paralysis stage and large areas of EDL 
muscle displayed complete NMJ denervation (data not shown), with the percent of motor endplate denervation 
being close to 80% (Figure 4B). Remarkably, masitinib treatment significantly prevented motor endplate dener-
vation with respect to vehicle-treated rats, exhibiting similar denervation values to paralysis onset (Figure 4B). 
The NMJ protection by masitinib was also evidenced in the functional inverted screen motor test (Figure 4C), 
where treatment improved the latency-to-fall by 15%–25 % from 5–15 days after onset .
Postparalysis masitinib treatment prevented the pathological remodeling of  Schwann cells and vascular networks asso-
ciated to progressive paralysis. Perisynaptic Schwann cells are glial cells at the NMJs that ensure the synapse 
stability, maintenance, and repair during damage or denervation (41). Perisynaptic Schwann cells respond to 
ALS-induced denervation with profound morphological and phenotypic changes (17), retracting processes 
from the NMJs while extending processes to other endplate areas (42). Therefore, we examined whether 
downregulation of  mast cells in masitinib-treated rats was associated to preservation of  perisynaptic Schwann 
cells in the EDL muscle, as analyzed by confocal microscopy followed by 3-D reconstructions. Figure 5A and 
Supplemental Figure 2 show that NMJ denervation correlated with fewer nestin+ and S100β+ perisynaptic 
Schwann cells overlapping with NMJs as compared with those in NonTg or paralysis-onset EDL muscles. 
In comparison, the number of  perisynaptic Schwann cells overlapping with NMJs was largely preserved in 
masitinib-treated rats (Figure 5A), being comparable with the number at the onset of  paralysis.
Figure 1. Endomysial infiltration and degranulation of mast 
cells in the extensor digitorum longus (EDL) muscle of SOD1G93A 
rats. Longitudinal cryostat sections of NonTg and SOD1G93A rat 
(onset and advanced paralysis) EDL muscles were stained with 
toluidine blue to visualize mast cells. (A) Few endomysial mast 
cells were observed in NonTg and mSOD1-onset EDL muscles as 
compared with numerous mast cells during advanced paralysis. 
Note the sharp increase in mast cell density between onset and 
advanced paralysis conditions (arrowheads indicate mast cells). 
Insets show a 40× magnification of Toluidine blue+ mast cells. 
(B) Representative toluidine blue images of different degranu-
lating mast cell morphologies during the advanced symptomatic 
stage, displaying the release of metachromatic granules. (C) 
Quantitative analysis showing the significant increase in mast 
cell number and degranulation correlating with paralysis progres-
sion. All quantitative data are expressed as mean ± SEM; data 
were analyzed by Kruskal-Wallis followed by Dunn’s multiple 
comparison test, *P < 0.01. (D) Representative confocal images 
showing immunoreactivity to tryptase, chymase, and c-Kit in 
mast cells (arrowheads) from advanced paralysis EDL muscle. 
Scale bar: 10 μm. n = 4–5 animals/condition.
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Figure 2. Spatial interaction of mast cells with motor nerve endings, neuromuscular junctions (NMJs), and macrophages during paralysis progression. 
Whole mount of extensor digitorum longus (EDL) muscles were processed for IHC and visualized in the confocal microscope. (A) Representative confocal 
images showing the interaction of mast cells with motor nerve endings and NMJs. Branches of motor axons were immunostained for anti-neurofilament 
(NF, white), motor endplates for α-bungarotoxin (α-BTX, red), and mast cells for tryptase (green, yellow arrowheads). Note the clustering of mast cells 
surrounding degenerating and fragmenting motor nerve endings and denervated NMJs during advanced paralysis (n = 4 animals/condition). (B) Compar-
ative analysis of mast cell density in EDL-muscle NMJ compartment (blue square) versus muscle parenchyma devoid of plates (yellow square). The graph 
shows the cell density expressed as number of cells per mm2 in a 100-μm Z-stack. Data are expressed as mean ± SEM: data were analyzed by Mann-Whit-
ney U test, 2-tailed, *P < 0.01. Confocal microphotograph in B is a representative image of the EDL muscle from a symptomatic SOD1G93A rat to illustrate 
the regions used for quantitative analysis. (C) Representation of the interaction of chymase+/tryptase+ mast cells (green, arrowheads) with motor nerve 
endings (gray) and NMJs endplates (α-BTX, red). The right panel shows a representative image of the interaction between CD11b+ macrophage–like cells 
(blue) with mast cells (yellow) in the surrounding of a NMJ (red). Scale bars: 50 μm (A) and 15 μm (C). n = 4 animals/condition for A and C. 
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Innervated muscles display a dense network of  capillaries that distribute along the interstitial spaces 
close to myofibrils (43). However, there is scarce knowledge about vascular remodeling occurring in mus-
cles affected in ALS. As shown in Figure 5B, regions with NMJ denervation in EDL muscle 15 days after 
paralysis onset displayed a systematic reduction of  capillary network, suggestive of  failing microcircula-
tion. A 15-day treatment with masitinib significantly prevented this pathological vascular remodeling, in 
parallel with preserved NMJ innervation.
Figure 3. Masitinib treatment reduces mast cell infiltration and degranulation into extensor digitorum longus (EDL) 
muscle during advanced paralysis. Masitinib (30 mg/kg) or vehicles were orally administered during 15 days after paral-
ysis onset, and rats were processed for histochemical analysis of the EDL muscles. (A and B) Representative microscopic 
fields of transversal sections of EDL muscle stained with toluidine blue, showing the number and degranulation of 
mast cells. Note the sharp reduction in mast cell number, size, and degranulating pictures in masitinib-treated rats as 
compared with controls. The graphs to the right show the quantitative analysis of the number of total mast cells (upper) 
and degranulating mast cells (lower) assessed in toluidine blue–stained sections. (C) Representative microscopic fields 
of transversal sections of EDL muscle immunostained with CD11b. Myofibers are delineated by dashed lines. Note the 
reduction of endomysial macrophage infiltrating the EDL muscles in masitinib-treated rats as compared with controls. 
The CD11b macrophage–like cell (yellow arrowheads) infiltration area was assessed by IHC. Values for paralysis onset and 
advanced paralysis–masitinib are expressed as percent respect to advanced paralysis–vehicle. All quantitative data are 
expressed as mean ± SEM; data were analyzed by Kruskal-Wallis followed by Dunn’s multiple comparison test, *P < 0.01. 
n = 4–5 animals/condition. Scale bar: 25 μm (C).
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Discussion
Here, we report that mast cells and macrophages directly interact with degenerating motor nerve endings 
and motor endplates in symptomatic SOD1G93A rats. In particular, the increased number and degranulation 
of  mast cells correlated with paralysis progression, suggesting mast cells may be deleterious for the mainte-
nance of  functional NMJs. Downregulation of  mast cells and macrophage infiltration by means of  system-
ic treatment with the tyrosine kinase inhibitor masitinib significantly reduced the rate of  NMJ denervation 
and motor deficits, further indicating inflammation as a relevant pathogenic mechanism aggravating distal 
axonopathy and paralysis progression in ALS. Masitinib also prevented the rapid pathological remodeling 
of  Schwann cells and capillary networks observed after paralysis onset, which is consistent with a preserved 
functioning of  the EDL muscle. Remarkably, our findings also provide a significant mechanism of  action 
for masitinib at degenerating NMJs, which may have clinical therapeutic relevance for ALS.
Previous studies have not paid attention to mast cell infiltration in affected muscles from ALS patients or 
animal models. In symptomatic SOD1G93A rats, we found striking changes in the number, phenotype, and spa-
Figure 4. Masitinib treatment 
prevented neuromuscular junction 
(NMJ) denervation. (A) Masitinib or 
vehicle was administered as described 
above and whole mounted extensor 
digitorum longus (EDL) muscles were 
processed for IHC. The panels show 
representative confocal images used 
to assess the innervation pattern 
of NMJs in different experimental 
conditions. α-Bungarotoxin-FITC 
(α-BTX, red) staining was used to 
analyze motor endplates. Synap-
tophysin–Alex Fluor 555 and heavy 
chain of neurofilaments–Alexa Fluor 
555 (green) were used to visualize the 
motor axon branches and presynaptic 
terminals. Insets show higher-magni-
fication images of innervated (yellow 
colocalization) or denervated (red) 
NMJs. Arrowheads indicate typical 
denervated motor endplates. Scales 
bars: 50 μm and 10 μm for insets. (B) 
The graph represents the quantitative 
analysis of NMJ occupancy defined 
as the overlapping of synaptophysin 
and α-BTX staining and expressed 
as percentage with respect to the 
nonTg condition. Note the massive 
loss of innervation occurring between 
onset and advanced paralysis in 
vehicle-treated rats and its prevention 
by masitinib. n = 4–5 animals/condi-
tion; at least 100 NMJs were analyzed 
per muscle, per animal. Data are 
expressed as mean ± SEM; data were 
analyzed by Kruskal-Wallis followed 
by Dunn’s multiple comparison test, 
*P < 0.01. (C) The inverted screen test 
was used to measure motor function. 
For each animal, hang time from an 
inverted grid was recorded in seconds 
and expressed as percent of the 
value of asymptomatic rats (100%). 
n = 14 and n = 22 for vehicle- and 
masitinib-treated groups, respectively. 
Data are expressed as mean ± SEM; 
data were analyzed by Mann-Whitney 
U test, 2-tailed, *P < 0.01.
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Figure 5. Masitinib prevented perisynaptic Schwann cell and capillary network remodeling in extensor digitorum longus (EDL) muscle during advanced 
paralysis. Longitudinal cryostat sections of NonTg and SOD1G93A rat (onset and advanced paralysis) EDL muscles were processed for IHC to visualize 
neuromuscular junctions (NMJs), perisynaptic Schwann cells, and the capillary network. (A) Representative 3-D reconstruction of the spatial interactions 
between α-bungarotoxin+ motor endplates (α-BTX, red) and perisynaptic S100β+ (magenta) and nestin+ (green) Schwann cells. Original confocal images are 
shown in Supplemental Figure 2. In normal NonTg rat EDL muscle, Schwann cells covered the endplates and filled the spaces between adjacent gutters 
(arrowheads). In contrast, during the symptomatic phase, most nestin+ and S100β+ cells progressively retracted from the NMJs no longer overlapping the 
motor endplates. Masitinib treatment prevented the associated retraction of Schwann cells from NMJs observed during advanced paralysis. (B) Represen-
tative images of capillary network assessed with tomato-isolectin staining (white) in EDL muscle areas with high density of motor nerve terminals (blue) 
and NMJ (red). Note the loss of capillary networks in symptomatic rats. The graph shows the quantitative analysis of total areas stained by lectin in NMJ-
rich regions in different experimental conditions. Data are expressed as mean ± SEM; data were analyzed by Kruskal-Wallis followed by Dunn’s multiple 
comparison test, *P < 0.01. n = 4 animals/condition. Scale bars: 50 μm (A) and 10 μm (B).
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tial location of mast cells in rat EDL muscle, installing in a short period of time (2 weeks) after paralysis onset. 
These changes are consistent with a causal association between the underlying neuromuscular pathology and a 
complex inflammatory process, likely orchestrated by degranulation of mast cells, further accelerating denerva-
tion. In comparison, mast cell degranulation has been described in patients with muscular dystrophy and auto-
immune myositis (22, 44), the cells likely inducing injury of myofibers and further recruitment of inflammatory 
cells through the secretion of proteases (45, 46). It is uncertain if  similar mast cell–mediated myofiber toxicity 
also occurs in ALS. Nonetheless, about half of ALS patients exhibit robust increases in serum creatine kinases 
(47), indicating sustained myofiber injury potentially mediated by mast cell infiltration. Thus, serum creatine 
kinase might be a useful biomarker of active mast cell–mediated pathology in ALS patients.
The finding of  frequent explosive mast cell degranulation in the EDL muscle during advanced paralysis 
is intriguing, and it anticipate multiple local responses mediated by secreted proteases, cytokines, trophic fac-
tors and vasoactive mediators (48). The release of  metachromatic granules indicates the secretion of  heparin 
derivatives, which promote regenerative pathways in muscle, mediated in part by FGF signaling (36). At the 
same time, heparan sulphate may impair the formation of  neuromuscular functions in vitro by direct bind-
ing to neural agrin (49). The unregulated or overstimulated mast cells can also lead to fibrosis and collagen 
deposition via the release of  several mediators, such as cytokines and TGFβ (50, 51). In turn, fibrosis could 
adversely affect motor nerve axon plasticity and growth, as well as NMJ reinnervation. A marked fibrotic 
process in skeletal muscle of  symptomatic SOD1G93A mice has been reported, involving increased deposition 
of  extracellular matrix molecules such as fibronectin and collagen I and -III (52). Mast cells can also release 
nerve growth factor (NGF) species, leading to the recruitment of  T-lymphocytes (53, 54) or deleterious sig-
naling through 75-kD neurotrophin receptor (p75NTR) receptors expressed in either motor nerve terminals or 
Schwann cells (55). Thus, degranulating mast cells have the potential to directly or indirectly trigger damage 
of  myofibers, motor nerve endings, Schwann cells, and capillary networks.
The proposed pathogenic role of  mast cells in the neuromuscular compartment appears to be in conflict 
with a previous report showing that developmental mutation in kit genes, which limits the expression of  c-Kit 
in SOD1G93A mice, results in reduced survival, despite having a decreased number of  mast cells in the spinal 
cord (56). However, this phenotype could be explained by different concomitant developmental alterations of  
mice, such as defective myelination and neural progenitors that might create increased vulnerability to mutant 
SOD1 overexpression. This scenario profoundly differs from our finding of  detrimental mast cell activity 
in ALS, which is spatially and temporally restricted to NMJ pathology during postparalysis stages. There-
fore, the appropriate functional phenotype or activation of  mast cells appears to be of  critical importance, as 
opposed to their absolute number in the neuromuscular compartment. Consequently, a preferred therapeutic 
strategy would be downregulation of  mast cell activity rather than their pharmacological depletion.
Little is known about the mechanisms of chemoattraction and differentiation of mast cell precursors to 
ALS-affected muscles. Primary myofiber damage associated with denervation or muscle-restricted expression 
of mutant SOD1 (57) is a plausible mechanism. Alternatively, a currently unknown mechanism of neurogenic 
recruitment of mast cells can be anticipated, as evidenced by the close spatial interaction between mast cells and 
degenerating motor nerve endings and denervated NMJs. A bidirectional interaction between nerves and mast 
cells is a well-recognized mechanism in neurogenic inflammation triggered by sensory and autonomic nerve 
endings (58, 59). This mechanism is known to be largely mediated by substance P released by axon terminals 
(60). Substance P does not seem to be expressed in healthy rodent motor neurons but rather is found in signif-
icant levels in muscle fibers (61). Other putative mast cell chemoattractant molecules in ALS-affected muscles 
include TNFα, NGF, and ATP produced by either degenerating motor nerve endings, denervated myofibers, 
perisynaptic Schwann cells, or inflammatory cells. Finally, intact motor nerve terminals release the neurokinin 
calcitonin gene related protein (CGRP) (62), also capable of modulating mast cell degranulation through specif-
ic receptors (58). It is reported that CGRP expression and release in motor neurons is involved in maintenance 
of NMJs and inversely correlated to neuronal survival (63). Thus, dysfunctional motor nerve terminals might 
trigger mast cell accumulation and activation in the neuromuscular compartment during ALS.
Mast cell accumulation in EDL muscle was paralleled by accumulation of  CD11b+ macrophage–like 
cells in the same neuromuscular compartment, suggesting a crosstalk between these immune cells as part 
of  a complex pathological process. Previous studies have described CD11b+ and CD68+ macrophage infil-
trates close to NMJs in SOD1G93A rats and mice (7, 64), a scenario that was partially reverted by protective 
interventions in ALS rats (64). Also, CD68+ macrophages infiltrating the interstitial space between myofi-
bers have been described in the skeletal muscle of  ALS patients (18).
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As expected, we found that tyrosine kinase inhibition with masitinib treatment downregulated the mast 
cell recruitment in degenerating EDL muscle, which in turn resulted in a significant and complete inter-
ruption of  NMJ denervation in the 15 days after paralysis onset. This mechanism of action of  masitinib in 
muscle was unknown and complementary to a previously described effect of  the drug-inhibiting neuroinflam-
mation in the lumbar spinal cord of  SOD1G93A rats (27). Thus, the significant increase in SOD1G93A rats after 
paralysis survival, when treated with masitinib at paralysis onset, might be explained by a simultaneous and 
probably synergist effect of  the drug on deleterious inflammation that accelerates paralysis progression.
Neuroprotection by masitinib was originally associated to inhibition of  tyrosine kinase receptor CSF-
1R in microglia and aberrant glial cells that typically proliferate after paralysis onset (27). Because masitinib 
inhibits various tyrosine kinases, including c-Kit, CSF-1R, PDGF-R, Lyn, and Fyn, it could potentially 
downregulate other cell types, including mast cells as well as monocytes and macrophages (25, 26). In 
particular, c-Kit receptor activation by stem cell factor is needed for the differentiation of  mast cells from 
precursors (65). It is presently unknown whether stem cell factor is upregulated in ALS-affected muscles; 
however, it could be expressed by Schwann cells, as described previously in neurofibromatosis type-1 (66).
Masitinib treatment also prevented the regressive remodeling of  perisynaptic Schwann cells described 
in ALS (67, 68). Because Schwann cell dissociation from NMJ is mainly caused by the axon retraction 
from motor plates (17, 68), our results further suggest the halt of  distal motor axon degeneration follow-
ing treatment with masitinib. A potential important finding for ALS pathogenesis is the almost complete 
disappearance we found of  capillaries in EDL muscle areas devoid of  NMJ innervation. This loss was 
prevented by masitinib. Degranulating mast cells could potentially mediate this effect through yet-unknown 
mechanisms. CNS microvascular pathology has been described in ALS (69) and could lead to local hypoxia 
further promoting recruitment of  mast cells, as has been reported in ischemia-reperfusion of  skeletal mus-
cle (70). A similar microcirculation failure has been reported in other neuromuscular pathologies such as 
spinal muscle atrophy or muscular dystrophy (71, 72).
In conclusion, the present study addressed one key issue about ALS pathogenesis and therapeutics: the 
identification of  mast cells orchestrating inflammation in the cellular microenvironment of  the neuromus-
cular compartment with the potential to accelerate NMJ denervation after paralysis onset. Mast cells were 
abundant in the endomysium during paralysis progression and typically clustered with macrophages close 
to motor nerve terminals, suggesting a neurogenic and/or myogenic induction. Moreover, pharmacological 
downregulation of  mast cells and other immune effectors with masitinib prevented not only NMJ dener-
vation, but also regressive changes in Schwann cells and capillary networks. These mechanisms of  action 
make masitinib a potentially novel ALS drug, capable of  exerting multifaceted neuroprotection in both 
central and peripheral nervous systems via selective kinase inhibition.
Methods
Animals. Male SOD1G93A progeny were used for further breeding to maintain the line (Taconic Biosciences 
Inc., NTac:SD-Tg(SOD1G93A)L26H). Rats were housed in a centralized animal facility with a 12-hour 
light-dark cycle with ad libitum access to food and water. Perfusion with fixative was performed under 90% 
ketamine (Phs Pharmaservice) and 10% xylazine (Xylased) anesthesia, and all efforts were made to mini-
mize animal suffering, discomfort or stress.
Experimental conditions. At least 4 rats were analyzed for each experiment. Four different conditions 
were studied as follows: i) NonTg rats 160–180 days old; ii) transgenic SOD1G93A rats 180–190 days old 
(symptomatic, onset); iii) transgenic SOD1G93A rats 195–210 days old treated with vehicle (symptomatic, 
advanced paralysis-vehicle), and iv) transgenic SOD1G93A rats 195–210 days old treated with 30 mg/kg/d of  
masitinib during 15 days (symptomatic, advanced paralysis-masitinib).
Determination of  disease onset and end-stage. As described previously (27), all rats were weighed and evaluat-
ed for motor activity daily. Disease onset was determined for each animal when pronounced muscle atrophy 
was accompanied by abnormal gait, typically expressed as subtle limping or dragging of  one hind limb. When 
necessary, end-stage was defined by a lack of  righting reflexes or the inability to reach food and water.
Masitinib administration. As described previously (27), only transgenic rats showing weakness and 
gait alterations in hind limbs as first clinical sign were selected for masitinib treatment studies. Male 
and female rats were divided randomly into the masitinib or vehicle-treated groups. Masitinib mesylate 
(AB1010, manufactured and provided by ABScience), freshly prepared in drinking sterilized water, was 
administrated daily at a dose of  30 mg/kg using a curved stainless steel gavage needle with 3-mm ball tip 
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(Kent Scientific Corp). Dosing was defined in accordance with previous studies in the same rat model of  
ALS that was shown to be safe for chronic treatments (27). Rats were treated from day 1 after paralysis 
for an additional 15 days, when they were then euthanized.
Inverted screen test. Twelve vehicle- and 16 masitinib-treated rats were placed on a metal grid screen 
(45 × 30 cm). After placement, the rats were allowed time to grip before the grid was inverted 50 cm over 
a cage containing fresh bedding. Latency to fall was recorded up to 30 seconds. Three independent mea-
surements were recorded 10 minutes apart during the day of  testing, and data of  3 measurements were 
averaged. Measurements started at approximately 5 months (1 month before onset, approximately) and 
continued during 15 days after onset. Latency to fall was plotted (percentage with respect to asymptom-
atic stage), considering the time of  grip during the asymptomatic stage as 100%.
IHC of  whole mounted muscle. Rats were deeply anesthetized using 90% ketamine and 10% xylazine 
anesthesia and were fixed by perfusion with 4% paraformaldehyde (MilliporeSigma) in PBS (Appli-
Chem). Extensor digitorium longus (EDL) muscles from the hind limb were dissected. Then, tissues 
were blocked for 2 hours at room temperature (5% BSA, 0.8% Triton X-100 in PBS), incubated with 
primary antibodies at 4°C overnight: 1:300 mouse monoclonal anti-nestin (GeneTex, GTX26142), 
1:400 mouse monoclonal anti-S100β (MilliporeSigma, S2532), 1:250 mouse monoclonal anti–CSF-
1R (Santa Cruz Biotechnology Inc., sc-46662), 1:300 rabbit polyclonal anti-Iba1 (Wako, 019-19741), 
1:250 mouse monoclonal anti-CD68 (Abcam, ab31630), 1:200 mouse monoclonal anti-CD11b (BD 
Biosciences, BD550299), 1:200 rabbit polyclonal anti-Tryptase (Abcam, ab134932), 1:250 mouse 
monoclonal anti-chymase (Abcam, ab2377), and rat polyclonal anti–c-Kit-Biotin (Abcam, ab25022). 
Then, tissue was washed with PBS 3 times for 5 minutes, incubated with secondary antibodies (1:500 
goat anti–mouse Alexa Fluor 633 [Thermo Fisher Scientific, A21052], 1:500 goat anti–rabbit Alexa 
Fluor 546 [Thermo Fisher Scientific, A11035] or -633 [Thermo Fisher Scientific, A21071], 1:500 
streptavidin-633 [Thermo Fisher Scientific, #S21375] and/or fluorescently labeled α-bungarotox-
in-FITC [α-BTX, Thermo Fisher Scientific, B13422]) for 2 hours at room temperature, washed with 
PBS 3 times for 15 minutes, and whole mounted in DPX mounting medium (MilliporeSigma) on 
slides. Axon staining was carried out using 1:1,000 heavy chain neurofilament-Alexa Fluor 555 (Mil-
liporeSigma, MAB5256A5), and axon presynaptic terminals were labeled with 1:300 synaptophysin–
Alexa Fluor 555 (Abcam, ab206870). Capillary networks were visualized using an isolectin-biotin/
streptavidin-633 1:300 probe (Thermo Fisher Scientific, I21414).
Comparative analysis of  mast cells in myofiber and NMJ compartments. Tryptase+ mast cells were counted in 
whole-mounted EDL muscle using a stereological approach, contrasting mast cell number in 2 predefined mus-
cle compartments: the region surrounding the motor end plates (NMJ compartment) versus muscle parenchyma 
devoid of plates. At least 50 confocal stacks (320 × 320 × 100 μm in Z-stacks) of 4 SOD1G93A symptomatic 
animals were analyzed as shown in Figure 2B.
NMJ analysis. Structural changes of  the NMJ were scored using maximum-intensity projections of  
images acquired from whole-mounted muscles. Briefly, NMJ innervation analysis was performed taking 
into consideration those postsynaptic motor endplates occupied by a presynaptic axon terminal, where full 
innervation was defined as at least 80% of  overlapping between pre- and postsynapsis. An average of  100 
NMJs per animal was analyzed using the ImageJ software.
Muscle cryopreserved sections. Paraformaldehyde (4%) fixed extensor muscle was dissected and cryopre-
served in 30% sucrose (MilliporeSigma) at 4°C. The 72-hour preserved muscle was embedded in TissueTek 
(Sakura) sectioned (longitudinal and transverse) at 10 μm using a cryostat and collected on gelatin-coated 
slides. Sections were blocked for 1 hour at room temperature (5% BSA, 0.5% Triton X-100 in PBS), incubated 
with primary antibodies overnight at 4°C (1:250 mouse monoclonal anti-Chymase [Abcam, ab2377], 1:250 
rat polyclonal anti–c-Kit-biotin [Abcam, ab25022], 1:200 rabbit polyclonal anti-tryptase [Abcam, ab134932], 
and 1:200 mouse monoclonal anti-CD11b [BD Bioscience, 550299]), washed with PBS 3 times for 10 min-
utes, incubated with secondary antibodies for 2 hours at room temperature (1:500 goat anti–rabbit Alexa 
Fluor 488 [Thermo Fisher Scientific, A11034], 1:500 goat anti–mouse Alexa Fluor 633 [Thermo Fisher Sci-
entific, A21052], and 1:500 streptavidin-Alexa Fluor 633 [Thermo Fisher Scientific, S21375]), washed with 
PBS 3 times for 5 minutes, and mounted in DPX.
Toluidine blue staining. For the mast cell analysis based in metachromasia observation, 10-μm sections of  
paraformaldehyde-fixed extensor muscle were cryostat sliced and mounted in gelatin-coated slides. Sections 
were washed and hydrated 2 times in distilled water for 10 minutes and embedded in 1% toluidine blue solu-
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tion for 10 minutes. Then, slides were washed in distilled water 3 times for 5 minutes and dehydrated during 3 
minutes in 70% ethanol, 3 minutes in 95% ethanol, and finally 2 minutes in 100% ethanol. Slides were cleared 
in xylene twice for 3 minutes each and finally mounted in DPX (MilliporeSigma). Images (10×, 20×, 40×, 
and 100×) were acquired using an Olympus CX41 microscope connected to a Evolution LC Color camera 
and using ImagePro Express software for adquicition. The number of  toluidine blue+ metachromatic mast 
cells was counted using the ImageJ software, in at least 40 fields per muscle per animal using a magnification 
of  10×. Degranulating mast cells, characterized by extensive metachromatic granules being released by an 
isolated mast cell, were counted using 20× magnification in serial pictures of  each muscle section.
Fluorescence Imaging. Fluorescence imaging was performed with a laser scanning confocal microscope 
(Zeiss LSM 880 or Zeiss LSM 800) with either a 25× (1.2 numerical aperture) objective or 63× (1.3 numer-
ical aperture) oil-immersion objective using Zeiss Zen Black software. Maximum intensity projections of  
optical sections were created with Zeiss Zen software, as were 3-D reconstructions.
Statistics. Quantitative data were expressed as mean ± SEM. Two-tailed Mann-Whitney test or Kru-
skal-Wallis followed by Dunn’s multiple comparison test were used for statistical analysis, with P < 0.01 
considered significant. GraphPad Prism 7.03 software was used for statistical analyses.
Study approval. All procedures using laboratory animals were performed in accordance with the nation-
al and international guidelines and were approved by the Institutional Animal Committee for animal exper-
imentation. All experimental procedures were approved by the Ethical Committee for the use of  Exper-
imental Animals (CEUA) of  the Institut Pasteur de Montevideo, Uruguay, and under the current ethical 
regulations of  the Uruguayan Law 18.611 for animal experimentation that follows the Guide for the Care 
and Use of  Laboratory Animals of  the National Institutes of  Health (National Academies Press, 2011).
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